Is Tilray Stock a Buy In December 2022?

Shares of cannabis-producer Tilray have underperformed the broader markets in the last three years. Is TLRY stock a buy right now?

| More on:
A cannabis plant grows.

Source: Getty Images

Shares of Canadian cannabis producer Tilray (TSX:TLRY) are down 50% in 2022 and 90% from all-time highs, valuing the company at a market cap of $2.7 billion.

Investors were initially flush with excitement when cannabis was legalized in Canada back in October 2018. Soon after the legalization, marijuana producers were impacted by rising competition, cannibalization from a thriving black market, a slow and painful licensing process, the COVID-19 pandemic, rising inventory levels, and mounting losses.

Several cannabis companies, including Tilray, plowed in millions of dollars to acquire companies and gain traction in various other markets. But pot producers were in high demand at the onset of marijuana legalization in Canada.

So, Tilray and peers paid a hefty premium to acquire these assets, weakening their balance sheet in the process. These overvalued acquisitions also resulted in billion-dollar goodwill impairments, driving share prices lower.

While Tilray increased sales from $175 million in fiscal 2019 to $628.3 million in fiscal 2022 (ended in May), its revenue in the last 12 months has fallen to $613.6 million.

Despite its market trailing performance in the last three years, let’s see if Tilray should be part of your equity portfolio in 2022.

Is Tilray stock a buy right now?

Tilray completed the big-ticket acquisition of Aphria last year, making it the largest Canadian producer. While the acquisition brought scale, it did little to improve Tilray’s balance sheet. Instead, the company reported its deepest net loss as a publicly listed company in fiscal 2022.

Tilray is now placing its bets on the United States to legalize marijuana at the federal level. The company is well-positioned to enter the largest cannabis market in the world. But there is a good chance the U.S. will take several years to legalize marijuana consumption federally.

To gain a foothold south of the border, Tilray acquired a few craft beer manufacturers and entered the cannabidiol-infused beverage market. It bought Montauk Brewing, a New York-based craft manufacturer, last month and acquired Colorado-based Breckenridge Distillery in 2021. Tilray also purchased companies such as SweetWater Brewing in 2020 and Manitoba Harvest in 2019 to expand its presence in the United States.

In fiscal Q1 of 2023, Tilray’s alcohol business reported sales of $20.7 million, accounting for 13% of total revenue. Alcohol sales were up 33% year over year, but cannabis revenue slumped 17% year over year to $58.6 million.

Tilray has diversified its revenue streams and is well poised to leverage its distribution network in the United States once cannabis is legalized in the country.

What next for TLRY stock and investors?

In addition to North America, Tilray is focused on entering new markets in Europe. It currently operates in Germany’s medical marijuana market. International cannabis sales stood at $10.4 million in fiscal Q1 of 2023. Germany is expected to legalize marijuana for recreational use by 2024, providing a significant tailwind for Tilray to grow sales in this region.

Several other countries from the European Union might follow suit. A report from BDS Analytics projects cannabis sales in this market to touch US$3.9 billion by 2025.

Tilray has multiple expansion opportunities in the next three years. But to address its depressed valuation, it has to shore up its balance sheet to regain investor confidence and stage a turnaround.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »